GLP-1R (co)-agonists first emerged as therapeutics for treatment of type 2 diabetes mellitus and have since become an established drug class for improving glycemic control. The interest in GLP-1 for obesity treatment has surged in 2015 after the approval of Saxenda (liraglutide).
Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity.
Moving forward, it's essential to keep these visual contexts in mind when discussing Glp-1 Analogs For Obesity Treatment In Humans.
Diet control, moderate exercise, behavior modification programs, bariatric surgery and prescription drug treatment are the major interventions used to help people lose weight. Among them, anti-obesity drugs have high compliance rates and cause noticeable short-term effects in reducing obese levels.
The interest in GLP-1 for obesity treatment has surged in 2015 after the approval of Saxenda (liraglutide). To date, GLP-1 analogs are primarily administered by s.c. injection, which poses a significant burden on patient compliance. To address this challenge, research has focused on oral delivery.
We investigated the anthropometric, demographic and clinical characteristics associated with total body weight loss (TBWL) from subcutaneous GLP-1 analogue therapy in patients with obesity in a real-world setting.
![Picture of glp-1_analogs [TUSOM | Pharmwiki] | Creatinine levels, Metformin, Treatment](https://i.pinimg.com/originals/81/bc/0b/81bc0bba452130d314757675f9b44b4c.png "glp-1_analogs [TUSOM | Pharmwiki] | Creatinine levels, Metformin, Treatment")
